Clinical Trials | January 14, 2026
GRIN Therapeutics launches global Phase 3 trial for groundbreaking GRIN-NDD therapy
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
GRIN-NDD is one of the most complex neurodevelopmental disorders with limited treatment options today
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation
The decision secures legal protection in China for semaglutide, the blockbuster drug underpinning Novo Nordisk’s diabetes and obesity treatments
The accelerated review covers WCK 5222 for multiple critical infections
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India
The move strengthens GBL’s clinical-stage presence in the United States
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
Subscribe To Our Newsletter & Stay Updated
